Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses

OBJECTIVE: Warfarin is an FDA-approved oral anticoagulant for long-term prevention of thromboembolism. Substantial inter-individual variation in dosing requirements and the narrow therapeutic index of this widely-prescribed drug make safe initiation and dose stabilization challenging. Single nucleot...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Burmester, James K., Berg, Richard L., Glurich, Ingrid, Yale, Steven H., Schmelzer, John R., Caldwell, Michael D.
Formato: Artigo
Idioma:Inglês
Publicado: Marshfield Clinic 2011
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3251364/
https://ncbi.nlm.nih.gov/pubmed/21562135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3121/cmr.2011.951
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares